At a glance
A short peptide discussed in respiratory and inflammatory cell research.
This profile separates the compound’s scientific background from specification-specific preparation and source schedules. Begin with the research findings and limitations, then select the formulation you want to examine.
How it works
Potential benefits & side effects
Interpret each outcome in the context of the study population, formulation and evidence type. Research findings do not establish a personal treatment outcome.
Potential benefits & research findings
The source includes experimental respiratory-tissue and immune-cell context. Such findings should not be presented as proof of improved breathing or treatment of lung disease.[1][5]
Read the original publications to see the measured endpoints, comparator, duration and uncertainty. Mechanistic plausibility and a favorable experimental result are different from demonstrated clinical benefit.
Side effects & evidence limitations
Interpret the reported adverse effects together with the study population, route and observation period. Small or short studies can miss uncommon and delayed harms. Evidence from a related compound does not establish the safety of Chonluten.
Source-reported adverse effects and cautions
Sources are available for independent reading. Individual claims and research schedules have not yet undergone an independent clinical review by Pep Science.
- Editorial responsibility
- Pep Science editorial desk
- Last independent review
- Not yet recorded
SPECIFICATIONS & SOURCE SCHEDULES
Explore a vial size
Select the exact formulation. Vial content, target dose and prepared concentration are different measurements.
Showing 20 mg · 1 source tables
Standard / Gradual Approach (3 mL = 6.67 mg/mL)
| Week | Daily Dose (mcg) | Units (per injection) (mL) |
|---|---|---|
| Weeks 1–2 | 250 mcg (0.25 mg) | 3.75 units (0.0375 mL) |
| Weeks 3–4 | 500 mcg (0.5 mg) | 7.5 units (0.075 mL) |
| Weeks 5–6 | 1,000 mcg (1 mg) | 15 units (0.15 mL) |
| Weeks 7–8 | 1,500 mcg (1.5 mg) | 22.5 units (0.225 mL) |
| Weeks 9–10 | 2,000 mcg (2 mg) | 30 units (0.30 mL) |
| Weeks 11–12 | 3,000 mcg (3 mg) | 45 units (0.45 mL) |
| Weeks 13–14 | 4,000 mcg (4 mg) | 60 units (0.60 mL) |
| Weeks 15–16 | 4,000 mcg (4 mg) | 60 units (0.60 mL) |
Frequency: Inject once daily subcutaneously. For ≤10‑unit (≤0.10 mL) administrations during Weeks 1–4, consider 30‑ or 50‑unit insulin syringes for improved readability.
Additional schedule context & duration
Concise summary of the once‑daily regimen.
- Goal: Support bronchopulmonary tissue function and modulate inflammatory pathways[1].
- Schedule: Daily subcutaneous injections for 8–16 weeks with gradual titration.
- Dose Range: 250–4,000 mcg daily with incremental increases every 1–2 weeks.
- Reconstitution: 3.0 mL per 20 mg vial (6.67 mg/mL) for accurate unit measurements.
- Storage: Lyophilized refrigerated or frozen; reconstituted refrigerated; avoid repeated freeze–thaw.
Suggested daily titration approach.
- Start: 250 mcg daily; increase by 250–500 mcg every 1–2 weeks as tolerated.
- Target: Up to 4,000 mcg daily by Weeks 13–16.
- Frequency: Once per day (subcutaneous).
- Cycle Length: 8–16 weeks; shorter durations (8–12 weeks) acceptable.
- Timing: Any consistent time; rotate injection sites.
Preparation
Reconstitution Steps
- Draw 3.0 mL bacteriostatic water with a sterile syringe.
- Inject slowly down the vial wall; avoid foaming.
- Gently swirl/roll until dissolved (do not shake).
- Label and refrigerate at 2–8 °C (35.6–46.4 °F), protected from light.
Storage Instructions
Proper storage preserves peptide quality[3].
- Lyophilized (short‑term): Refrigerate at 4 °C (39.2 °F) in dry, dark conditions.
- Lyophilized (long‑term): Store at −20 °C (−4 °F) or colder; minimize moisture exposure.
- Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within days to weeks and avoid freeze–thaw.
- Allow vials to reach room temperature before opening to reduce condensation uptake.
Injection Technique
General subcutaneous guidance from clinical best‑practice resources[4][7].
- Clean the vial stopper and skin with alcohol; allow to dry.
- Pinch a skinfold; insert the needle at 45° into subcutaneous tissue using a 25–27 gauge, ⅝‑inch needle[4].
- Do not aspirate for subcutaneous injections; inject slowly and steadily[4].
- Rotate sites systematically (abdomen, thighs, upper arms) to avoid lipohypertrophy[8].
Materials & quantity planning
Source materials checklist · 20 mg
Plan based on an 8–16 week daily protocol with gradual titration.
-
Peptide Vials (Chonluten, 20 mg each):
- 8 weeks ≈ 3 vials (45.5 mg total)
- 12 weeks ≈ 6 vials (115.5 mg total)
- 16 weeks ≈ 12 vials (227.5 mg total)
-
Insulin Syringes (U‑100):
- Per week: 7 syringes (1/day)
- 8 weeks: 56 syringes
- 12 weeks: 84 syringes
- 16 weeks: 112 syringes
-
Bacteriostatic Water (10 mL bottles): Use 3.0 mL per vial for reconstitution.
- 8 weeks (3 vials): 9 mL → 1 × 10 mL bottle
- 12 weeks (6 vials): 18 mL → 2 × 10 mL bottles
- 16 weeks (12 vials): 36 mL → 4 × 10 mL bottles
-
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- Per week: 14 swabs (2/day)
- 8 weeks: 112 swabs → recommend 2 × 100‑count boxes
- 12 weeks: 168 swabs → recommend 2 × 100‑count boxes
- 16 weeks: 224 swabs → recommend 3 × 100‑count boxes
Calculate a phased quantity
Enter each finite phase from the schedule you are studying. Open-ended phases need an explicit duration. Calculation uses 20 mg per vial and 3 mL per vial.
Complete each phase to calculate totals.
Quantity estimates exclude preparation losses and expiry. Follow the formulation’s handling and disposal requirements.
FOLLOW THE EVIDENCE
References & further reading
Original publications and source documents cited across this product’s variants. A listed source is not an independent endorsement of a dosing schedule.
- 03
Source document
Sigma-Aldrich — Peptide Handling Guide (storage, reconstitution, and stability recommendations) (opens in a new tab)www.sigmaaldrich.com
Back to overview ↑ - 04
Public health resource
CDC (Subcut Injection PDF) — You Call the Shots: Subcutaneous Injection Technique (opens in a new tab)www.cdc.gov
Back to overview ↑ - 06
Public health resource
CDC — Preventing Unsafe Injection Practices (clinical safety guidance) (opens in a new tab)www.cdc.gov
Back to overview ↑ - 08
Public health resource
NCBI Bookshelf — Best practices for injection (asepsis, preparation, and administration) (opens in a new tab)www.ncbi.nlm.nih.gov
Back to overview ↑ - 09
Research publication
Subcutaneous Drug Injection Review (PMC) — Pharmacologic considerations of the subcutaneous route (opens in a new tab)pmc.ncbi.nlm.nih.gov
Back to overview ↑
Continue exploring
Related topics are not interchangeable compounds or formulations.